Olga Kaliebe, MD
Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1003810417
Payments from drug & device makers
Across 197 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$750
- Amgen$698
- Dexcom, Inc.$523
- Lilly USA, LLC$461
- Sanofi-aventis U.S. LLC$374
- Bayer$312
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,10498%
- Education$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $750 |
| Amgen(2 entities) | 27 | $698 |
| Dexcom, Inc. | 25 | $523 |
| Lilly USA, LLC | 14 | $461 |
| Sanofi-aventis U.S. LLC | 10 | $374 |
| Bayer | 8 | $312 |
| Amneal Pharmaceuticals LLC | 16 | $295 |
| Insulet Corporation | 11 | $231 |
| AbbVie | 10 | $198 |
| Boehringer Ingelheim | 5 | $191 |
| Medtronic(2 entities) | 4 | $171 |
| Astellas Pharma US Inc | 4 | $126 |
| Amryt Pharma Holdings Ltd | 1 | $122 |
| Radius Health, Inc. | 4 | $86 |
| Boston Scientific | 4 | $75 |
| Tandem Diabetes Care, Inc. | 2 | $71 |
| Foundation Medicine, Inc. | 1 | $66 |
| Abbott | 3 | $53 |
| Baxter Healthcare | 1 | $39 |
| Corcept Therapeutics | 2 | $36 |
| AstraZeneca | 2 | $35 |
| Rhythm Pharmaceuticals, Inc. | 1 | $35 |
| Soleno Therapeutics, Inc. | 2 | $34 |
| Zealand Pharma US, Inc. | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Mannkind Corporation | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
| Blue Earth Diagnostics | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,190 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $166,532 |
| OzempicSemaglutide | 90 | $136,311 |
| TymlosAbaloparatide | 29 | $80,683 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $25,477 |
| TrulicityDulaglutide | 28 | $25,056 |
| FarxigaDapagliflozin Propanediol | 17 | $22,317 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $17,308 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $14,311 |
| SynthroidLevothyroxine Sodium | 37 | $3,997 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,357 |
| Hydrocortisone | 33 | $2,336 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,674 |
| Levothyroxine Sodium | 184 | $1,310 |
| Ibandronate Sodium | 27 | $772 |
| Metformin Hcl ErMetformin Hcl | 67 | $683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $191 | $166,532126 claims |
| Novo NordiskOzempic | $750 | $136,31190 claims |
| Radius Health, Inc.Tymlos | $86 | $80,68329 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $374 | $25,47717 claims |
| Lilly USA, LLCTrulicity | $461 | $25,05628 claims |
| AstraZenecaFarxiga | $35 | $22,31717 claims |
| AbbVieSynthroid | $198 | $3,99737 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $295 | $1,402196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Tampa
- Andrew HenryTampa$929K
- Manuel Sainz de la PenaTampa$247K
- Yuvraj KumbkarniTampa$189K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.